Earnings Summary

Crinetics Pharmaceuticals Inc’s revenue jumped 125.06% since last year same period to $0.99Mn in the Q2 2023. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -63.12% fall in its revenue since last 3-months.

Crinetics Pharmaceuticals Inc’s net profit fell -20.3% since last year same period to $-50.98Mn in the Q2 2023. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -10.84% fall in its net profits since last 3-months.

Crinetics Pharmaceuticals Inc’s net profit margin jumped 46.54% since last year same period to -5159.82% in the Q2 2023. On a quarterly growth basis, Crinetics Pharmaceuticals Inc has generated -200.54% fall in its net profit margins since last 3-months.

Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.81 - a 2.41% jump from last quarter’s estimates.

Crinetics Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.81.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Crinetics Pharmaceuticals Inc’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Crinetics Pharmaceuticals Inc’s return on equity (ROE) stands at -0.57.